Treatment of pancreatic cancer is shifting toward an increasing use of neoadjuvant therapies before surgical resection,
1 and the role of radiotherapy remains an intense area of research. Recent randomized trials comparing neoadjuvant chemoradiotherapy with neoadjuvant chemotherapy alone have not proven a benefit in this setting.
2,3 The dose, fractionation, volume, duration, adaptive technology, and rational combinations with systemic agents are active areas of investigation.
4 Little, however, has been explored in the adjuvant setting. The authors sought to evaluate the selective use of radiotherapy postoperatively, when more information on tumor properties and resection margin status is available. …